Biologic therapy and introduction of biosimilars for severe psoriasis in Kaunas, Lithuania

July 7, 2016NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES

View at Publisher

Ask AI

Bookmark

Share

Key Points

The report aims to present the clinical experience with biologics and biosimilars for severe psoriasis treatment in Lithuania.
Evaluated medical data of psoriatic patients treated with biologics from 2009 to 2016
Assessed treatment outcomes using the Psoriasis Area and Severity Index (PASI)
Calculated mean body mass index (BMI) from patients' weight and height records
46 patients with severe plaque psoriasis received biologic treatments
10 patients treated with Infliximab, including 2 with reference products and 8 with biosimilars
Remaining patients included 16 treated with Ustekinumab and 20 with Etanercept
Average age of patients was 43.90 years with a mean psoriasis duration of 20.98 years
Significant decrease in PASI from baseline 26.83 to 1.66 observed

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

This report evaluates biologic and biosimilar treatments for severe psoriasis in Lithuania, indicating treatment gaps.

No takes yet. Share an insight, caveat, or question.

Subotinaitė et al. (2016) studied this question.

View at Publisher

Ask AI

Bookmark

Share